ST13, Hsp70 interacting protein pseudogene 11Genealiases: []
Q-omics provides the consensus-scored ST13P11 profile across patient tissues and cancer cell-line models. ST13P11 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, ST13P11 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ST13P11 RNA expression shows 10,297 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, KIRC, and THYM as cancer lineages where ST13P11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ST13P11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ST13P11 survival associations across molecular data types. ST13P11 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ST13P11 RNA expression–survival associations across cancer types. High ST13P11 expression shows unfavorable associations in STAD, SARC, KIRP and BRCA, but favorable associations in ESCA and CHOL. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify STAD as the clearest survival context for ST13P11 RNA expression.
This table summarizes ST13P11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ST13P11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ST13P11 shows lower tumor expression in THCA and BLCA and higher tumor expression in KIRC, LIHC, HNSC and ESCA. The KIRC box plot shows higher ST13P11 RNA expression in tumor versus normal tissue (log2 FC = +0.087, t-test p = .027).
This table shows molecular features associated with ST13P11 in patient tissues and cancer cell lines. In patient samples, ST13P11 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
